Additional file 2 : Figure S2. Effects of RTIs alone or in combination with BRAFi in different BRAF-mutant melanoma cells. (A) A375 and WM115 have been exposed to encorafenib (BRAFi) starting from 5 μM and then diluted 1:2 for 10 times in the presence or not of SPV122 at fixed dose of 1.25 μM to measure cell viability through MTT assay after 72 h. (B) The same experimental approaches have been performed in M14 cells in the presence of a BRAFi and/or efavirenz used at of 2.5 μM. (C) M14, A375 and WM115 cells have been treated with SPV122 starting from 5 μM and then diluted 1:2 for 10 times to measure cell viability through MTT assay after 72 h.